24/7 Market News Snapshot 29 May, 2025 – Alzamend Neuro, Inc. Common Stock (NASDAQ:ALZN)

May 29, 2025

DENVER, Colo., 29 May, 2025 (www.247marketnews.com) – (NASDAQ:ALZN) are discussed in this article.
Alzamend Neuro, Inc. (ALZN) is witnessing a remarkable surge in its market activity, with shares trading at $5.375, marking a staggering increase of 61.90% from the previous close of $3.320 in pre-market trading. The uptick has been accompanied by a trading volume of 2.44 million shares, signaling robust investor confidence in the company’s innovative pursuits within the neuropharmaceutical sector. Analysts are monitoring this trend closely, as such significant movements in stock prices often reflect changing investor sentiment, indicating potential opportunities for growth in the near future.

Amidst this bullish market response, Alzamend has also made headlines with the successful dosing of the first patient in its Phase II clinical study of AL001. This pioneering trial, which targets healthy human subjects, aims to assess the efficacy of AL001 as a novel lithium delivery system compared to traditional lithium carbonate products. By focusing on the pharmacokinetics of lithium, the study will analyze blood levels and brain absorption, marking a critical advancement in treatment methodologies for conditions such as Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.

Utilizing cutting-edge technology, including a specialized head coil developed by Tesla Dynamic Coils, the trial is conducted in partnership with prominent research hospitals, underscoring Alzamend’s dedication to medical innovation. Preliminary animal studies have indicated that AL001 may enhance lithium absorption in the brain while decreasing systemic levels. This approach has the potential to streamline treatment processes by reducing the necessity for therapeutic drug monitoring, addressing one of the primary challenges associated with current lithium therapies.

Stephan Jackman, the CEO of Alzamend, highlighted the significance of this advancement, which could positively impact over 43 million Americans grappling with these conditions. The company aims to release topline data from this critical study by the end of 2025, reinforcing its commitment to developing transformative solutions for patients.

Related news for (ALZN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.